Compare AbbVie Inc (ABBV) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Microchip Technology Inc. — how do they compare? AbbVie Inc trades at $253.47 (market cap $449.91B), while Microchip Technology Inc. trades at $85.17 (market cap $45.69B). The key difference: AbbVie Inc is far larger — about 9.8× Microchip Technology Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | MCHP | |
|---|---|---|
Market Cap | $449.91B | $45.69B |
Sector | Health | Technology |
52-Week High | $261.07 | $102.97 |
52-Week Low | $184.85 | $49.02 |
Enterprise Value | $513.38B | $50.99B |
Dividend Yield | 2.72% | 2.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Microchip Technology (MCHP) trades at $84.15, down 0.58% on the day, with a bearish technical signal but strong analyst support. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.57 exceeding the $0.505 forecast. The company benefits from AI-driven semiconductor demand, aerospace and defense growth, and new product launches like the TimePictra 12 platform. However, 2025 saw a net loss of $500,000 on revenue of $4.40 billion, though 2026 projections indicate a return to profitability with a 4.88% net margin.
MCHP presents a mixed outlook: robust growth catalysts in AI and aerospace contrast with high valuation multiples (P/E of 398.14) and recent profitability challenges. The consensus price target of $115.45 suggests 37% upside, but investors face risks from debt levels and market volatility. The stock's near-term direction hinges on execution of its Q2 2026 earnings and sustained demand in key sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
